Genentech, Hoffmann-La Roche, and Biogen have settled their BPCIA litigation against Dr. Reddy’s Laboratories (“DRL”) and Fresenius Kabi. As we previously reported, Genentech, Hoffmann-La Roche, and Biogen filed a complaint in the U.S. District Court for the District of New Jersey in November 2023, alleging that DRL’s proposed rituximab biosimilar to RITUXAN, DRL_RI, infringed 15 patents. The parties entered into a joint stipulation last week, dismissing all claims. The court then ordered the case dismissed.
This was the third BPCIA litigation involving a rituximab biosimilar, following cases against Sandoz and Celltrion which were dismissed in 2018 after the parties reached settlements in their respective cases.
The post Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation appeared first on Big Molecule Watch.